Article Versions Notes

Kadota H, Yuge R, Shimizu D, Miyamoto R, Otani R, Hiyama Y, Takigawa H, Hayashi R, Urabe Y, Kitadai Y, et al. Anti-Programmed Cell Death-1 Antibody and Dasatinib Combination Therapy Exhibits Efficacy in Metastatic Colorectal Cancer Mouse Models. Cancers. 2022; 14(24):6146. https://doi.org/10.3390/cancers14246146

Kadota, Hiroki, Ryo Yuge, Daisuke Shimizu, Ryo Miyamoto, Rina Otani, Yuichi Hiyama, Hidehiko Takigawa, Ryohei Hayashi, Yuji Urabe, Yasuhiko Kitadai, and et al. 2022. "Anti-Programmed Cell Death-1 Antibody and Dasatinib Combination Therapy Exhibits Efficacy in Metastatic Colorectal Cancer Mouse Models" Cancers 14, no. 24: 6146. https://doi.org/10.3390/cancers14246146

Kadota, H., Yuge, R., Shimizu, D., Miyamoto, R., Otani, R., Hiyama, Y., Takigawa, H., Hayashi, R., Urabe, Y., Kitadai, Y., Oka, S., & Tanaka, S. (2022). Anti-Programmed Cell Death-1 Antibody and Dasatinib Combination Therapy Exhibits Efficacy in Metastatic Colorectal Cancer Mouse Models. Cancers, 14(24), 6146. https://doi.org/10.3390/cancers14246146